BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medicis (MRX) 4Q Profit Falls, May Sell LipoSonix Unit


2/28/2011 8:20:05 AM

Phoenix Business Journal - by Angela Gonzales -- Just when I was getting excited about the prospect of trying Medicis Pharmaceutical Corp.’s LipoSonix fat-busting device, Chairman and CEO Jonah Shacknai said in a conference call with investors today that the Scottsdale company will begin looking to sell it off.

Medicis’ investors have not been warm to the idea of the dermatological company expanding into the fat-busting technology, which is undergoing clinical trials and is years away from FDA approval.

Next week, plans call for reaching out to companies interested in buying LipoSonix.

“We believe and always believed LipoSonix is a great technology that delivers highly predictable, consistent results,” Shacknai told investors. “We also believe this technology is better suited to a company that specializes in capital equipment and might have more latitude from a regulatory perspective than we do on a worldwide basis.”

The product originally was meant to be a platform for growth in the capital equipment market, but regulatory delays make this less attractive for a pharmaceutical company than it was a few years ago, he said.

“There is also a significant burn rate with LipoSonix products as they wait to gain FDA approval,” he said.

Still, Shacknai said Medicis (NYSE:MRX) will continue to seek FDA approval for the LipoSonix system in the U.S.

Shacknai said the company is considering various forms of divestiture that could even leave Medicis with a minority, noncontrolling interest.

Meanwhile, the company will continue to build its diversified research and development pipeline in its core dermatology and facial aesthetics franchise.

Medicis has signed four R&D transactions within the past six months and is in active negotiations for several more, Shacknai said. The company has $750 million in cash, putting it in a good position as a buyer.

“We have 15 projects under significant development, including two discovery programs, seven preclinical programs and six Phase II and Phase III programs,” he said, adding that none of those projects are related to LipSonix.

“Significantly, we believe at least seven of 15 development projects have peak revenue potential of greater than $75 million,” Shacknai said.

For the year ended Dec. 31, Medicis reported about $123 million in net income on $700 million in revenue. That is up considerably from about $76 million in net income on total revenue of $572 million in 2009.

The company’s stock closed at $25.82 today, about midway between its 52-week high of $30.94 and its low of $21.02.



Medicis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES